India aims to release indigenous Covid-19 vaccine by Independence Day
India’s topmost medical research body said that it is attempting to launch the world’s first Covid-19 vaccine on August 15. However, health experts have questioned the short timeline.
The order by Balram Bhargava, director general of the Indian Council of Medical Research (ICMR) on Friday directs 12 hospitals selected for carrying out clinical trials of Covaxin to ensure that the subject enrolment is initiated in the next few days.
“It is envisaged to launch the vaccine for public health use latest by 15 August after completion of all clinical trials. Bharat Biotech is working expeditiously to meet the target. However, the final outcome will depend on the cooperation of all clinical trial sites involved," said Bhargava.
ICMR has partnered with 12 institutes for human trials of COVAXIN— NewsBytes (@NewsBytesApp) July 3, 2020
These studies typically involve hundreds to thousands of volunteers and are conducted over several months, but given the current health emergency, ICMR is moving to expedite the trial process pic.twitter.com/Ugop19qWRF
“Non-compliance will be viewed very seriously,” Bhargava wrote in his letter
The candidate vaccine, Covaxin, is developed by Bharat Biotech, a Hyderabad-based pharmaceutical company, in partnership with the National Institute of Virology, an ICMR laboratory.
Bharat Biotech is a drug manufacturer that delivers 4 billion doses around the world for infections like rotavirus, hepatitis, Zika, Japanese encephalitis and others.
But Covaxin is yet to enter the clinical trials phase, a stage that other vaccine candidates across the world have already raced to. The earliest any of these expect to determine safety and efficacy is not until second quarter of next year.
It is for this reason health experts have expressed concern about the crunched timeline and even criticized this hurried approach. Many maintained that any clinical trial would take at least one year to complete all essential steps that include a three-phased trial followed by safety efficacy study, side-effect profile and antibody analyses.
Experts and investigators express concern
“It will be a very challenging and difficult task, considering that we have to look at both efficacy and safety of any vaccine that is introduced,” said Randeep Guleria, the head of the clinical research group of the national task force for Covid-19.
What’s more data about the vaccine’s preclinical performance has not been made public yet.
Investigators point out that vaccine development timelines are taxing and tedious beginning from virus isolation to vaccine licencing. The Ebola vaccine, for instance, also saw an expedited global response. Work commenced in 2014 resulting in the vaccine licensed after five years.
“Developing an effective vaccine is a time-consuming process. Recruitment of participants in itself can take months even if we try to expedite everything like we are doing for Covid-19,” said Anant Bhan, a researcher in bioethics and global health.
“Even with accelerated timelines, this seems rushed, and hence with potential risks, inadequate attention to the process.”
This will be the most egregious human clinical trial in Indian history if ICMR is intent on completing the trial in about 43 days & makes the vaccine available to the public latest by August 15.@AnantBhan @spkalantri @d_s_thakur @ICMRDELHIhttps://t.co/nZHWmBV1Fi via @RPrasad12— R. Prasad (@RPrasad12) July 3, 2020
The number of cases of the coronavirus disease in India is more than 625,000 and the country’s death toll is above 18,000.
A global race is underway to develop and mass-produce an effective vaccine to counter the new, deadly, and highly infectious coronavirus disease, COVID-19 that has brought much of the world to a standstill.
There are more than 100 vaccines in preclinical development by pharmaceutical companies, academic institutions, government agencies, and others.
Seventeen vaccine candidates, across at least ten countries, are already undergoing clinical trials. However, no vaccine has yet been approved for commercial use.
Daily newsletterReceive essential international news every morningSubscribe